Written opinion issued in Boston/Cook case:
This article was originally published in Clinica
A US district court judge has issued its written opinion confirming its decision in favour of Boston Scientific over litigation with Cook concerning its agreement with Guidant over drug-coated stents (see Clinica No 1012, p 13). In the written opinion, the court found the Guidant/Cook agreement was a "de facto sublicence" that was "neither authorised, permitted, nor lawful". Boston plans to submit its motion for an injunction on July 15 and the briefing on this motion will conclude by August 19.
You may also be interested in...
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.